Welcome to our dedicated page for Fortress Biotech SEC filings (Ticker: FBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fortress Biotech, Inc. (Nasdaq: FBIO) SEC filings page on Stock Titan provides access to the company’s regulatory documents filed with the U.S. Securities and Exchange Commission. These filings include current reports on Form 8-K, registration statements such as Form S-1, and other periodic disclosures that describe material events, financing arrangements and portfolio developments across Fortress and its subsidiaries.
Recent Form 8-K filings detail items such as amendments to the company’s credit agreement with Oaktree Fund Administration, LLC, including an extension of the loan maturity date and revised financial covenants tied to product net sales at Journey Medical Corporation. They also describe the issuance of warrants to purchase shares of Fortress common stock, with terms such as exercise price, anti-dilution adjustments and expiration date. Other 8-Ks report FDA-related milestones, including the issuance of a Complete Response Letter for CUTX-101, subsequent resubmission of the New Drug Application by Sentynl Therapeutics, and Fortress’ press releases on quarterly financial results.
The Form S-1 registration statement reproduced in part here explains Fortress Biotech’s business model, outlines its network of subsidiaries and partner companies, and registers the resale of shares issuable upon exercise of warrants granted in connection with its credit facility. It also describes risk factors, forward-looking statements and other information relevant to investors evaluating FBIO securities.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight key terms, financial obligations and corporate actions, helping readers quickly understand the implications of documents that can span many pages. Users can review filings related to common stock and preferred stock listed on the Nasdaq Capital Market, as well as disclosures about royalty arrangements, subsidiary transactions and regulatory events that may affect Fortress Biotech’s capital structure and operations.
Fortress Biotech, Inc. reported that the U.S. Food and Drug Administration has issued a complete response letter for CUTX-101 (copper histidinate). A complete response letter generally means the FDA has finished reviewing an application but cannot approve it in its present form. Fortress disclosed this development through a press release dated October 1, 2025, which is attached as an exhibit to the report.